OBJECTIVE: To determine whether hyperandrogenism in anovulatory women affects body fat distribution. DESIGN: Prospective nonrandomized study. SETTING: An academic research environment. PATIENT(S): Ten hyperandrogenic anovulatory patients and 10 healthy women matched by body mass index. INTERVENTION(S): Regional body fat analysis was performed before and after 3 months of GnRH analogue (GnRH-a) therapy. MAIN OUTCOME MEASURE(S): Body fat distribution was measured by waist-to-hip circumference ratio, single-slice computed tomography imaging (L2-3 interspace), and total body dual-energy x-ray absorptiometry. RESULT(S): Weight, body mass index, waist-to-hip circumference ratio, total body and leg fat mass, and subcutaneous adipose area were unaffected by the presence of hyperandrogenism or the use of GnRH-a therapy. Basal abdominal fat mass, abdomen-to-leg fat mass ratio, visceral adipose area, and total visceral adipose volume were comparable in both study groups. The abdominal fat mass increased in both groups during GnRH-a therapy, whereas the abdomen-to-leg fat mass ratio rose significantly only in the hyperandrogenic patients. During GnRH-a therapy, the hyperandrogenic patients demonstrated a significant increase in visceral adipose area compared with the healthy women so that total visceral adipose volume increased significantly in the former but not the latter. CONCLUSION(S): Three months of GnRH-a administration preferentially increased abdominal fat, as measured by single-slice computed tomography imaging and total body dual-energy x-ray absorptiometry, in hyperandrogenic anovulatory women.
OBJECTIVE: To determine whether hyperandrogenism in anovulatory women affects body fat distribution. DESIGN: Prospective nonrandomized study. SETTING: An academic research environment. PATIENT(S): Ten hyperandrogenic anovulatory patients and 10 healthy women matched by body mass index. INTERVENTION(S): Regional body fat analysis was performed before and after 3 months of GnRH analogue (GnRH-a) therapy. MAIN OUTCOME MEASURE(S): Body fat distribution was measured by waist-to-hip circumference ratio, single-slice computed tomography imaging (L2-3 interspace), and total body dual-energy x-ray absorptiometry. RESULT(S): Weight, body mass index, waist-to-hip circumference ratio, total body and leg fat mass, and subcutaneous adipose area were unaffected by the presence of hyperandrogenism or the use of GnRH-a therapy. Basal abdominal fat mass, abdomen-to-leg fat mass ratio, visceral adipose area, and total visceral adipose volume were comparable in both study groups. The abdominal fat mass increased in both groups during GnRH-a therapy, whereas the abdomen-to-leg fat mass ratio rose significantly only in the hyperandrogenicpatients. During GnRH-a therapy, the hyperandrogenicpatients demonstrated a significant increase in visceral adipose area compared with the healthy women so that total visceral adipose volume increased significantly in the former but not the latter. CONCLUSION(S): Three months of GnRH-a administration preferentially increased abdominal fat, as measured by single-slice computed tomography imaging and total body dual-energy x-ray absorptiometry, in hyperandrogenic anovulatory women.
Authors: Edward L Melanson; Kathleen M Gavin; Karen L Shea; Pamela Wolfe; Margaret E Wierman; Robert S Schwartz; Wendy M Kohrt Journal: J Appl Physiol (1985) Date: 2015-09-03
Authors: Karen L Shea; Kathleen M Gavin; Edward L Melanson; Ellie Gibbons; Anne Stavros; Pamela Wolfe; John M Kittelson; Sheryl F Vondracek; Robert S Schwartz; Margaret E Wierman; Wendy M Kohrt Journal: Menopause Date: 2015-10 Impact factor: 2.953
Authors: Daniel A Dumesic; Alin L Akopians; Vanessa K Madrigal; Emmanuel Ramirez; Daniel J Margolis; Manoj K Sarma; Albert M Thomas; Tristan R Grogan; Rasha Haykal; Tery A Schooler; Bette L Okeya; David H Abbott; Gregorio D Chazenbalk Journal: J Clin Endocrinol Metab Date: 2016-08-29 Impact factor: 5.958
Authors: Erica Keller; Gregorio D Chazenbalk; Paul Aguilera; Vanessa Madrigal; Tristan Grogan; David Elashoff; Daniel A Dumesic; David H Abbott Journal: Endocrinology Date: 2014-04-15 Impact factor: 4.736